Chemotherapy-induced peripheral neurotoxicity (CIPN): What we need and what we know

Journal of the Peripheral Nervous System

Volumn 19, Issue 2, 2014, Pages 66-76

  Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Chemotherapy; Neuropathy; Pathogenesis; Toxicity; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY; CONFERENCE PAPER; HUMAN; NEUROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; SOCIOECONOMICS; ADVERSE DRUG REACTION; COMPLICATION; ECONOMICS; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84925357246     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12073     Document Type: Conference Paper

References (98)

1. Abbi KK, Rizvi SM, Sivik J, Thyagarajan S, Loughran T, Drabick JJ (2010). Guillain-Barre syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature. Leuk Res 34:e154-e156.
2. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000). The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25-32.
3. Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014). Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 3:CD005228. Doi: 10.1002/14651858.CD005228.pub4.
4. Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G (2014). Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257-264.
5. Aoki M, Kurauchi Y, Mori A, Nakahara T, Sakamoto K, Ishii K (2014). Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats. Biol Pharm Bull 37:322-326.
6. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP (2008). A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34:368-377.
7. Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, Lonardi S, Cortinovis D, Cazzaniga M, Campagnolo M, Santos C, Kalofonos HP (2012a). Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. Eur J Neurol 20:788-794.
8. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012b). Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51-77.
9. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2012c). Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438-444.
10. Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP (2012d). Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23:3116-3122.
11. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2013). Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438-444.
12. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pinter T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bee V, Santana MJ, Miller DP, Lalla D, Slamon DJ (2013). Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 18:812-818.
13. Avivi I, Chakrabarti S, Kottaridis P, Kyriaku C, Dogan A, Milligan DW, Linch D, Goldstone AH, Mackinnon S (2004). Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplant 34:137-142.
14. Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R (2013). Carfilzomib inmultiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 27:1707-1714.
15. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010). Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144.
16. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20:2959-2967.
17. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Steffens CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I, Bendahmane B, Andre T, Kubicka S (2013). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29-37.
18. Berger A, Dukes EM, Oster G (2004). Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 5:143-149.
19. Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS (2013). Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer 49:2910-2918.
20. Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D (2012). Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118:2207-2216.
21. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL (2001). Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6:441-445.
22. Canta A, Chiorazzi A, Cavaletti G (2009). Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16:1315-1324.
23. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478-3483.
24. Cavaletti G (2011). Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist 16:1667-1668.
25. Cavaletti G, Marmiroli P (2010). Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657-666.
26. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D (1992). Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 84:364-371.
27. Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG (2001). Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37:2457-2463.
28. Cavaletti G, Petruccioli MG, Marmiroli P, Rigolio R, Galbiati S, Zoia C, Ferrarese C, Tagliabue E, Dolci C, Bayssas M, Griffon Etienne G, Tredici G (2002). Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res 22:4199-4204.
29. Cavaletti G, Nicolini G, Marmiroli P (2008). Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci 13:3506-3524.
30. Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E (2010). Chemotherapy-induced neuropathy. Curr Treat Options Neurol 13:180-190.
31. Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E (2011a). Chemotherapy-induced neuropathy. Curr Treat Options Neurol 13:180-190.
32. Cavaletti G, Alberti P, Marmiroli P (2011b). Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12:1151-1161.
33. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG (2012). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454-462.
34. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454-462.
35. Ceresa C, Cavaletti G (2011). Drug transporters in chemotherapy induced peripheral neurotoxicity: current knowledge and clinical implications. Curr Med Chem 18:329-341.
36. Ceresa C, Avan A, Giovannetti E, Geldof AA, Cavaletti G, Peters GJ (2014). Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. Anticancer Res 34:517-523.
37. Chakupurakal G, Etti RJ, Murray JA (2011). Peripheral neuropathy as an adverse effect of imatinib therapy. J Clin Pathol 64:456.
38. Chamberlain MC (2010). Neurotoxicity of cancer treatment. Curr Oncol Rep 12:60-67.
39. CI-PeriNoms (2009). CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study. J Peripher Nerv Syst 14:69-71.
40. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schoffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG (2013). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302.
41. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL (2012). A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18:248-255.
42. Fitzpatrick TR, Edgar L, Holcroft C (2012). Assessing the relationship between physical fitness activities, cognitive health, and quality of life among older cancer survivors. J Psychosoc Oncol 30:556-572.
43. Fumoleau P, Coudert B, Isambert N, Ferrant E (2007). Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18:v9-v15.
44. Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061.
45. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A (2008). Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188-1189 author reply 1189-1190.
46. Grisold W, Cavaletti G, Windebank AJ (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14:iv45-54.
47. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL (2011). Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29:421-427.
48. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312.
49. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ (2013). Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 22:1223-1231.
50. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767-774.
51. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol 32(18):1941-1967.
52. Hochster HS, Grothey A, Childs BH (2007). Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028-4029.
53. Hoke A (2012). Animal models of peripheral neuropathies. Neurotherapeutics 9:262-269.
54. Ip V, Liu JJ, Mercer JF, McKeage MJ (2010). Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol Pain 6:53.
55. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010). Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15:82-87.
56. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS (2012). An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 12:310-318.
57. Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ (2011). Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther 338:537-547.
58. Joseph EK, Levine JD (2009). Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain 10:534-541.
59. Kanat D, Bagdas D, Ozboluk HY, Gurun MS (2013). Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. J BUON 18:1012-1018.
60. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL (2010). The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19:1769-1777.
61. Kurniali PC, Luo LG, Weitberg AB (2010). Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology (Williston Park) 24:289-292.
62. Lavoie Smith EM, Cohen JA, Pett MA, Beck SL (2011). The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. Oncol Nurs Forum 38:133-142.
63. Lévi F, Jean-Louis M, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel J-P, Kunstlinger F, Lecouturier S, Descorps-Declére A, Jasmin C, Bismuth H, Reinberg A (1992). A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900.
64. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset J-L (1993). Oxaliplatin activity against metastatic colorectal cancer. a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A:1280-1284.
65. Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, McKeage MJ (2009). Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol 64:847-856.
66. Liu JJ, Lu J, McKeage MJ (2012). Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Curr Cancer Drug Targets 12:962-986.
67. Liu JJ, Kim Y, Yan F, Ding Q, Ip V, Jong NN, Mercer JF, McKeage MJ (2013a). Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol 85:207-215.
68. Liu X, Zhang G, Dong L, Wang X, Sun H, Shen J, Li W, Xu J (2013b). Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B up-regulation in rats. Neurochem Res 38:1973-1979.
69. Lucchetta M, Lonardi S, Bergamo F, Alberti P, Velasco R, Argyriou AA, Briani C, Bruna J, Cazzaniga M, Cortinovis D, Cavaletti G, Kalofonos HP (2012). Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol 70:899-902.
70. Marmiroli P, Nicolini G, Miloso M, Scuteri A, Cavaletti G (2012). The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity. Ital J Anat Embryol 117:75-97.
71. Meregalli C, Chiorazzi A, Carozzi VA, Canta A, Sala B, Oggioni N, Ceresa C, Foudah D, La Russa F, Miloso M, Nicolini G, Marmiroli P, Bennett DL, Cavaletti G (2013). Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle 13:612-621.
72. Merkies IS, Hughes RA (2010). The measurement of disease. J Neurol Neurosurg Psychiatry 81:943.
73. Merkies IS, Lauria G, Faber CG (2012). Outcome measures in peripheral neuropathies: requirements through statements. Curr Opin Neurol 25:556-563.
74. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ (2009). A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15:7085-7091.
75. Pastorelli F, Derenzini E, Plasmati R, Pellegrini C, Broccoli A, Casadei B, Argnani L, Salvi F, Pileri S, Zinzani PL (2013). Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 54:2318-2321.
76. Peltier AC, Russell JW (2006). Advances in understanding drug-induced neuropathies. Drug Saf 29:23-30.
77. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012). Healthcare costs andworkloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848.
78. Postma TJ, Heimans JJ (2000). Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513.
79. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998). Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744.
80. Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, Novotny PJ, Lachance DH, Loprinzi CL (2012). Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171-5178.
81. Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, Cavaletti G (2011). Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain 7:29.
82. Schiff D, Wen PY, van den Bent MJ (2009). Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 6:596-603.
83. Scuteri A, Galimberti A, Maggioni D, Ravasi M, Pasini S, Nicolini G, Bossi M, Miloso M, Cavaletti G, Tredici G (2009). Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30:312-319.
84. Scuteri A, Galimberti A, Ravasi M, Pasini S, Donzelli E, Cavaletti G, Tredici G (2010). NGF protects Dorsal Root Ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci Lett 486:141-145.
85. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH (2012). Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 20:3355-3364.
86. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013). Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359-1367.
87. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714.
88. Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A (2013). Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110:11199-11204.
89. Staff NP, Podratz JL, Grassner L, Bader M, Paz J, Knight AM, Loprinzi CL, Trushina E, Windebank AJ (2013). Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 39:124-131.
90. Ta LE, Espeset L, Podratz J, Windebank AJ (2006). Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992-1002.
91. Toyama S, Shimoyama N, Ishida Y, Koyasu T, Szeto HH, Shimoyama M (2014). Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies. Anesthesiology 120:459-473.
92. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M (2012). An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractorymultiplemyeloma who have been previously treated with bortezomib. Br J Haematol 158:739-748.
93. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA (2002). Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336-4342.
94. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL (2012). The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20:625-632.
95. Xu XT, Dai ZH, Xu Q, Qiao YQ, Gu Y, Nie F, Zhu MM, Tong JL, Ran ZH (2013). Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin induced sensory neuropathy in digestive tract cancers: a meta-analysis. J Dig Dis 14:288-298.
96. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189.
97. Zheng H, Xiao WH, Bennett GJ (2011). Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 232:154-161.
98. Zinzani PL, Derenzini E, Pellegrini C, Celli M, Broccoli A, Argnani L (2013). Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. Br J Haematol 163:681-683.